ABIVAX Société Anonyme
ABVXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, ABIVAX Société Anonyme (ABVX) is listed under Biotechnology. With a market capitalization of $10.57B, it sits in large-cap territory. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Market Cap
$10.57B
Beta
-0.19
P/E (TTM)
—
P/E (Fwd)
-52.20
EPS (TTM)
$-5.36
EPS (Fwd)
$-2.54
ROE
-157.1%
ROA
-44.6%
Cash
$491.6M
Total Debt
$34.2M
Free CF
-$114.5M
52W Change
1988.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $491.6M in cash comfortably exceeding the $34.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$114.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -157.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -0.19 suggests ABVX is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ABVX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.